Ircon bags Mumbai Metro Line-5 contract worth Rs 471.30 crore from MMRDA
The scope includes the design, manufacturing, supply, installation, testing, and commissioning of a 220 kV receiving substation, along with 220 kV, 33 kV, and 25 kV cabling. It also covers the complete 25 kV overhead catenary system, switching stations, auxiliary power distribution systems, SCADA systems, and installation of lifts and escalators across parts of the main line, stations, and Kasheli Depot.
The contract comes with a 108-week design and build timeline, followed by a two-year defect liability period and five years of comprehensive maintenance. The project will play a crucial role in strengthening the power infrastructure of Mumbai's growing metro network.
The order is a domestic works contract and underscores Ircon's deep expertise in executing complex rail infrastructure projects in India.
In the meantime, the company also received a Letter of Award from Rail Vikas Nigam Ltd for a ₹755.78 crore railway project in Madhya Pradesh. The contract covers civil and electrical works for the new Pipaliya Nankar–Budni broad-gauge line. IRCON will execute the project in JV with JPWIPL, holding a 70% stake. IRCON's share is valued at ₹529.05 crore, and the project will be completed in 36 months, plus a 6-month defect liability period.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
10 hours ago
- Business Upturn
Nifty top gainers and losers today, August 12: Tech Mahindra, Maruti Suzuki, Hero MotoCorp among top performers
The Indian benchmark indices closed lower today, with the Nifty 50 slipping 0.40% to end at 24,487.40 and the Sensex dropping 0.46% to close at 80,235.59. Despite the overall market weakness, several stocks managed to post notable gains, while others faced significant losses. Here's a look at Nifty top gainers and losers that drove the day's action (as per Trendline) for the day: Among the top gainers on the Nifty, Tech Mahindra was up 2.0% to close at 1,511.2, followed by Maruti Suzuki, which rose 2.0% to 12,847. Hero MotoCorp gained 1.8%, ending at 4,644, while Mahindra & Mahindra advanced 1.6% to 3,236.5. NTPC also saw a rise of 1.2%, closing at 340.1. Other notable gainers included Sun Pharmaceutical (up 1.1% to 1,626.5), Cipla (up 1.1% to 1,521.6), Tata Steel (up 1.0% to 160.2), Coal India (up 0.8% to 385.4), and Oil and Natural Gas, which increased 0.7% to 235.4. On the downside, Bajaj Finance led the losers with a 2.8% decline, closing at 853. Trent fell 1.4% to 5,368, and Hindustan Unilever dropped 1.4% to 2,484. Eternal declined 1.3% to 305.3, while HDFC Bank slipped 1.3% to 1,969.9. Nestle India was down 1.3% at 1,091.1, and Tata Consumer Products fell 1.1% to 1,047.7. Bajaj Auto lost 1.1%, closing at 8,186, followed by ICICI Bank down 1.1% to 1,421.4, and Bharat Electronics which decreased 1.0% to 380.3. Overall, while the market faced pressure on August 12, these top gainers and losers highlighted the mixed investor sentiment across key sectors. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Hero MotocorpMaruti SuzukiTech Mahindra Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
10 hours ago
- Business Upturn
PN Gadgil shares soar 8% as Q1 net profit jumps 96.3% YoY to Rs 69.3 crore, revenue up 2.8%
PN Gadgil Jewellers shares surged nearly 8% in Tuesday's trade after the company reported an impressive set of Q1 results, driven by strong profitability and margin expansion. As of 2:20 PM, the shares were trading 7.42% higher at Rs 589.35. The jewellery retailer posted a net profit of ₹69.3 crore for the quarter ended June 2025, a sharp 96.3% jump from ₹35.3 crore in the same period last year. Revenue grew 2.8% year-on-year to ₹1,714.5 crore from ₹1,668 crore, reflecting steady sales despite a challenging retail environment. Operational performance was also robust, with EBITDA rising 71.5% to ₹109.9 crore compared to ₹64.1 crore last year, while margins improved significantly to 6.4% from 3.8% a year ago, indicating better cost control and higher efficiency. On the market front, the stock opened at ₹551.50 and gained momentum, hitting an intraday high of ₹603.50 against a low of ₹548.00. The counter remains well above its 52-week low of ₹473.80 but is still some distance from its 52-week high of ₹848.00. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12 hours ago
- Business Upturn
Alkem Laboratories Q1 Results: Revenue jumps 11.2% YoY to Rs 3,371 crore, net profit up Rs 21.45% YoY
By Aman Shukla Published on August 12, 2025, 13:40 IST Alkem Laboratories has delivered a strong set of numbers for the first quarter of FY26, with growth across revenue, profit, and operational performance. The company reported a consolidated net profit of ₹668 crore, marking a solid 21.45% year-on-year jump from ₹550 crore in the same quarter last year. Revenue also saw healthy growth, rising 11.2% to ₹3,371 crore compared to ₹3,031.8 crore a year ago. The pharmaceutical major's EBITDA stood at ₹739 crore, up 21.35% from ₹609 crore, with margins improving to 21.9% from 20% in the previous year. The domestic business remained the key growth driver, clocking sales of ₹2,265 crore, a 12% increase from the previous year, contributing 68.3% to total sales. According to IQVIA (SSA) data, the company outperformed the Indian Pharmaceutical Market (IPM) in seven therapies, including Gastrointestinal, Vitamins/Minerals/Nutrients, Pain Management, Anti-Diabetics, Neuro/CNS, Respiratory, and Dermatology, with growth ranging from 1.1x to 2.3x the market rate. On the international front, sales stood at ₹1,053.9 crore, registering an 8.9% year-on-year rise. The US business contributed ₹698.2 crore, up 8.8% from last year and accounting for 21% of total sales. Non-US international markets generated ₹355.6 crore, up 9.1%, contributing 10.7% to total revenue. In the US market, Alkem filed its first Biologics License Application (BLA), received five ANDA approvals (including two tentative), and launched three new products during the quarter. As of June 30, 2025, the company had filed 185 ANDAs, two NDAs, and one BLA with the USFDA, receiving approvals for 160 ANDAs (including 15 tentative) and both NDAs. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
